<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CALCIUM CHANNEL BLOCKERS " code="CO8CA-001" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blocker, of the orthostatic hypotension sort, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
